VCXB 10X Capital Venture Acquisition Corp. III
- 10.980
- +0.020+0.18%
10X Capital Venture Acquisition Corp. III News
10X Capital Venture Acquisition Corp. III Gets Non-Compliance Notice From NYSE American
10X Capital Venture Acquisition Corp. III (VCXB) said late Tuesday it received a notice from the NYSE American that it is not compliant with the exchange's listing rules due to its failure to timely f
10X Capital Venture Acquisition Corp. III Receives NYSE Notice Regarding Late Form 10-K Filing
New York, NY, April 23, 2024 (GLOBE NEWSWIRE) -- 10X Capital Venture Acquisition Corp. III (NYSE:VCXB) ("10X III"), announced today that New York Stock Exchange Regulation, Inc., by letter dated April 17, 2024 (the
10X Capital Venture Acquisition Corp. III Receives NYSE Notice Regarding Noncompliance
New York, NY, Jan. 31, 2024 (GLOBE NEWSWIRE) -- 10X Capital Venture Acquisition Corp. III (NYSE:VCXB, VCXB.U, VCXB WS)) ("10X III"), announced today that NYSE Regulation ("NYSER"), by letter dated January 29, 2024
10X Capital Venture Acquisition Corp. III: Thomas Will Remain as Chmn of the Bd of Directors >VCXB
10X Capital Venture Acquisition Corp. III: Thomas Will Remain as Chmn of the Bd of Directors >VCXB
10X Capital Venture Acquisition Corp. III David Weisburd, Te Current Oper Chief and Head of Origination, to Succeed Hans Thomas as CEO >VCXB
10X Capital Venture Acquisition Corp. III David Weisburd, Te Current Oper Chief and Head of Origination, to Succeed Hans Thomas as CEO >VCXB
10X Capital Venture Acquisition Corp. III Announces Expected Change in Management
NEW YORK, NY (United States), Jan. 08, 2024 (GLOBE NEWSWIRE) -- 10X Capital Venture Acquisition Corp. III ("10X III") (NYSE:VCXB), a publicly traded special purpose acquisition company, announced today that, subject
10X Capital Venture Acquisition Receives Non-Compliance Notice From New York Stock Exchange
10X Capital Venture Acquisition Corp. III (VCXB) said late Tuesday it has been notified that it is not in compliance with the NYSE American's listing requirements for failure to timely file its quarte
10X Capital Venture Acquisition Corp. III Receives NYSE Notice Regarding Late Form 10-Q Filing
New York, NY, Nov. 28, 2023 (GLOBE NEWSWIRE) -- 10X Capital Venture Acquisition Corp. III (NYSE:VCXB) ("10X III"), announced today that New York Stock Exchange Regulation, Inc., by letter dated November 21, 2023 (the
10X Capital Venture to Transfer Listing of Securities to NYSE American From NYSE
10X Capital Venture Acquisition Transfers Its Listed Securities To The NYSE American
10X Capital Venture Acquisition Transfers Its Listed Securities To The NYSE American
10X Cap Venture Acquisition Corp. III Announces Transfer of Listed Securities to the NYSE Amer
10X Cap Venture Acquisition Corp. III Announces Transfer of Listed Securities to the NYSE Amer
SPAC 10X Capital III to Merge With HIV Therapy Developer Addimmune
10X Capital Venture Acquisition Corp. III Agrees to Business Combination With American Gene Technologies
10X Capital Venture Acquisition Corp. III (VCXB) has agreed to merge with American Gene Technologies International in an equity transaction worth $500 million in pre-money enterprise value for the gen
Addimmune, Clinical Stage HIV-Focused Gene Therapy Company, To Go Public Through Business Combination With SPAC 10x Capital Venture Acquisition Corp. III
Addimmune, Clinical Stage HIV-Focused Gene Therapy Company, To Go Public Through Business Combination With SPAC 10x Capital Venture Acquisition Corp. III
Addimmune: Boards of Directors of Addimmune and 10X III Have Unanimously Approved Proposed Merger, Which Is Expected to Be Completed 1Q 2024 >VCXB.U
Addimmune: Boards of Directors of Addimmune and 10X III Have Unanimously Approved Proposed Merger, Which Is Expected to Be Completed 1Q 2024 >VCXB.U
Addimmune: Jeff Galvin, CEO of AGT, Will Become the CEO of Addimmune >VCXB.U
Addimmune: Jeff Galvin, CEO of AGT, Will Become the CEO of Addimmune >VCXB.U
Addimmune: Is a Clinical-Stage Gene and Cell Therapy Co Developing a Functional Cure for HIV, Prior to the Combination, Non-HIV Assets Will Spin Off Into Entity That Will Retain the Amer Gene Technologies Name >VCXB.U
Addimmune: Is a Clinical-Stage Gene and Cell Therapy Co Developing a Functional Cure for HIV, Prior to the Combination, Non-HIV Assets Will Spin Off Into Entity That Will Retain the Amer Gene Technolo
American Gene Technologies Intl Inc., 10X Cap Venture Acquisition Corp. III: Entered Into Merger Agreement That Would Result in Combined Co Being Publicly Listed and Renamed Addimmune >VCXB.U
American Gene Technologies Intl Inc., 10X Cap Venture Acquisition Corp. III: Entered Into Merger Agreement That Would Result in Combined Co Being Publicly Listed and Renamed Addimmune >VCXB.U
Addimmune: Combined Co Is Expected to Trade Under Symbol 'HIV' >VCXB.U
Addimmune: Combined Co Is Expected to Trade Under Symbol 'HIV' >VCXB.U
Addimmune, a Clinical Stage Hiv-Focused Gene Therapy Company, to Go Public Through Business Combination With 10x Capital Venture Acquisition Corp. III
Addimmune's investigational cell therapy, AGT103-T, makes gene modifications to the patients' immune cells (T cells) that harden those cells against HIV infection and depletion, thus allowing those ce
Analysis
Price Target
No Data
